Quarterly report pursuant to Section 13 or 15(d)


9 Months Ended
Sep. 30, 2023
Receivables [Abstract]  
The following table sets forth the details of the Company’s accounts receivable balances and allowance for credit losses as of September 30, 2023, and December 31, 2022:
($ in thousands) September 30, 2023 December 31, 2022
Accounts receivable $ 48,650  $ 45,097 
Allowance for credit losses (430) (559)
Accounts receivable, net $ 48,220  $ 44,538 
The Company generally does not require collateral from its customers, although it may require letters of credit in certain instances to limit its credit risk.
The Company did not have any customer concentrations in accounts receivable as no one customer represented over 10% of the Company’s accounts receivable balances as of September 30, 2023. One customer, a large multinational medical device and healthcare company, represented over 10% of the Company’s accounts receivable balances as of December 31, 2022. The same customer represented 11.9% of the Company’s revenue during the nine months ended September 30, 2022, (see also Note 2—Revenue Recognition).
The Company accounts for credit losses under the current expected credit loss model using a “loss rate methodology,” which considers historical loss rates on its trade accounts receivable balances, adjusted for current conditions, along with reasonable and supportable forecasts regarding collections and delinquencies on trade accounts receivable.